3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
23
Advanced Breast Cancer
2
Sarcoma, Endometrial Stromal
1
Recurrence
1
Perivascular Epithelioid Cell Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Endometrial Neoplasms
1
ER+ Breast Cancer
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Neoplasms, Male
1
Breast Diseases
1
Breast Cancer Patients
1
Brain Neoplasms
1
Brain Diseases
1
Advanced ER+, HER2-Negative Breast Cancer
1
Adenosarcoma of the uterus
1
Interventions
Temozolomide
3
XENP 1595
2
Trastuzumab
2
Sodium Chloride
2
Dexmedetomidine
2
Cancer Vaccines
2
Adjuvants, Immunologic
2
veliparib
1
tucatinib
1
tipifarnib
1
sagopilone
1
pembrolizumab
1
interferon gamma-1b
1
glutathione pegylated liposomal doxorubicin
1
elacestrant
1
abemaciclib
1
Saline Solution
1
Rituximab
1
Radiotherapy
1
Radiation
1
RAD1901
1
Oncolytic Virotherapy
1
Interferon-gamma
1
Immunotherapy
1
Dasatinib
1
Craniotomy
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Central Nervous System Diseases
×
elacestrant
×
Clear all
NCT05386108
2026-04-06
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled